Skip to main content
SpringerLink
Log in

Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression

  • Chapter
Hepatitis C Virus Disease

  • 652 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abdelmalek, M.F., Firpi, R.J., Soldevila-Pico, C., Reed, A.I., Hemming, A.W., Liu, C., Crawford, J.M., Davis, G.L., Nelson, D.R. (2004). Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation, 10: 199–207.

    PubMed  Google Scholar 

  • Adam, R., McMaster, P., O’Grady, J.G., Castaing, D., Klempnauer, J.L., Jamieson, N., Neuhaus, P., Lerut, J., Salizzoni, M., Pollard, S., Muhlbacher, F., Rogiers, X., Garcia Valdecasas, J.C., Berenguer, J., Jaeck, D., Moreno Gonzalez, E. (2003). Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transplantation, 9: 1231–1243.

    PubMed  Google Scholar 

  • Afdhal, N., Freilich, B., Levine, R., Black, M., Brown, R., Jr., Mansour, H., O’Brien, M., Brass, C. (2004). Colchicine versus PEG-Interferon long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology, 40: 239A.

    Google Scholar 

  • Ahmad, J., Dodson, S.F., Demetris, A.J., Fung, J.J., Shakil, A.O. (2001). Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alpha alone versus interferon alpha and ribavirin. Liver Transplantation, 7: 863–869.

    PubMed  CAS  Google Scholar 

  • Alberti, A.B., Belli, L.S., Airoldi, A., de Carlis, L., Rondinara, G., Minola, E., Vangeli, M., Cernuschi, A., D’Amico, M., Forti, D., Pinzello, G. (2001). Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transplantation, 7: 870–876.

    PubMed  CAS  Google Scholar 

  • Armstrong, G.L., Alter, M.J., McQuillan, G.M., Margolis, H.S. (2000). The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology, 31: 777–782.

    PubMed  CAS  Google Scholar 

  • Azzaroli, F., Accogli, E., Nigro, G., Trere, D., Giovanelli, S., Miracolo, A., Lodato, F., Montagnani, M., Tame, M., Colecchia, A., Mwangemi, C., Festi, D., Roda, E., Derenzini, M., Mazzella, G. (2004). Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World Journal of Gastroenterology, 10: 3099–3102.

    PubMed  CAS  Google Scholar 

  • Benvegnu, L., Chemello, L., Noventa, F., Fattovich, G., Pontisso, P., Alberti, A. (1998). Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer, 83: 901–909.

    PubMed  CAS  Google Scholar 

  • Berardi, S., Lodato, F., Gramenzi, A., D’Errico, A., Lenzi, M., Bontadini, A., Morelli, M.C., Tame, M.R., Piscaglia, F., Biselli, M., Sama, C., Mazzella, G., Pinna, A.D., Grazi, G.L., Bernardi, M., Andreone, P. (2006). High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut. Jun 23 [Epub ahead of print].

    Google Scholar 

  • Berenguer, M. (2003). Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplantation, 9: S44–47.

    PubMed  Google Scholar 

  • Berenguer, M., Ferrell, L., Watson, J., Prieto, M., Kim, M., Rayon, M., Cordoba, J., Herola, A., Ascher, N., Mir, J., Berenguer, J., Wright, T.L. (2000). HCV-related fibrosis progression following liver transplantation: increase in recent years. Journal of Hepatology, 32: 673–684.

    PubMed  CAS  Google Scholar 

  • Berenguer, M., Lopez-Labrador, F.X., Wright, T.L. (2001). Hepatitis C and liver transplantation. Journal of Hepatology, 35: 666–678.

    PubMed  CAS  Google Scholar 

  • Berenguer, M., Palau, A., Fernandez, A., Benlloch, S., Aguilera, V., Prieto, M., Rayon, J.M., Berenguer, J. (2006). Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplantation, 12: 1067–1076.

    PubMed  Google Scholar 

  • Berenguer, M., Prieto, M., Cordoba, J., Rayon, J.M., Carrasco, D., Olaso, V., San-Juan, F., Gobernado, M., Mir, J., Berenguer, J. (1998). Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. Journal of Hepatology, 28: 756–763.

    PubMed  CAS  Google Scholar 

  • Bizollon, T., Ahmed, S.N., Radenne, S., Chevallier, M., Chevallier, P., Parvaz, P., Guichard, S., Ducerf, C., Baulieux, J., Zoulim, F., Trepo, C. (2003). Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut, 52: 283–287.

    PubMed  CAS  Google Scholar 

  • Bizollon, T., Pradat, P., Mabrut, J.Y., Chevallier, M., Adham, M., Radenne, S., Souquet, J.C., Ducerf, C., Baulieux, J., Zoulim, F., Trepo, C. (2005). Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. American Journal of Transplantation, 5: 1909–1913.

    PubMed  Google Scholar 

  • Brillanti, S., Vivarelli, M., De Ruvo, N., Aden, A.A., Camaggi, V., D’Errico, A., Furlini, G., Bellusci, R., Roda, E., Cavallari, A. (2002). Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transplantation, 8: 884–888.

    PubMed  Google Scholar 

  • Bruno, S., Silini, E., Crosignani, A., Borzio, F., Leandro, G., Bono, F., Asti, M., Rossi, S., Larghi, A., Cerino, A., Podda, M., Mondelli, M.U. (1997). Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology, 25: 754–758.

    PubMed  CAS  Google Scholar 

  • Burak, K.W., Kremers, W.K., Batts, K.P., Wiesner, R.H., Rosen, C.B., Razonable, R.R., Paya, C.V., Charlton, M.R. (2002). Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transplantation, 8: 362–369.

    PubMed  Google Scholar 

  • Burra, P., Targhetta, S., Pevere, S., Boninsegna, S., Guido, M., Canova, D., Brolese, A., Masier, A., D’Aloiso, C., Germani, G., Tomat, S., Fagiuoli, S. (2006). Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Transplantation Proceedings, 38: 1127–1130.

    PubMed  CAS  Google Scholar 

  • Camma, C., Giunta, M., Andreone, P., Craxi, A. (2001). Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. Journal of Hepatology, 34: 593–602.

    PubMed  CAS  Google Scholar 

  • Castells, L., Vargas, V., Allende, H., Bilbao, I., Luis Lazaro, J., Margarit, C., Esteban, R., Guardia, J. (2005). Combined treatment with PEGylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. Journal of Hepatology, 43: 53–59.

    PubMed  CAS  Google Scholar 

  • Chalasani, N., Manzarbeitia, C., Ferenci, P., Vogel, W., Fontana, R.J., Voigt, M., Riely, C., Martin, P., Teperman, L., Jiao, J., Lopez-Talavera, J.C. (2005). PEGinterferon alpha-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology, 41: 289–298.

    PubMed  CAS  Google Scholar 

  • Chiaramonte, M., Stroffolini, T., Vian, A., Stazi, M.A., Floreani, A., Lorenzoni, U., Lobello, S., Farinati, F., Naccarato, R. (1999). Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer, 85: 2132–2137.

    PubMed  CAS  Google Scholar 

  • Colombo, M., de Franchis, R., Del Ninno, E., Sangiovanni, A., De Fazio, C., Tommasini, M., Donato, M.F., Piva, A., Di Carlo, V., Dioguardi, N. (1991). Hepatocellular carcinoma in Italian patients with cirrhosis. New England Journal of Medicine, 325: 675–680.

    PubMed  CAS  Google Scholar 

  • Cotler, S.J., Ganger, D.R., Kaur, S., Rosenblate, H., Jakate, S., Sullivan, D.G., Ng, K.W., Gretch, D.R., Jensen, D.M. (2001). Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation, 71: 261–266.

    PubMed  CAS  Google Scholar 

  • Crippin, J.S., McCashland, T., Terrault, N., Sheiner, P., Charlton, M.R. (2002). A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation, 8: 350–355.

    PubMed  Google Scholar 

  • Czaja, A.J. (2002). Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transplantation, 8: 505–513.

    PubMed  Google Scholar 

  • Davis, G.L., Albright, J.E., Cook, S.F., Rosenberg, D.M. (2003). Projecting future complications of chronic hepatitis C in the United States. Liver Transplantation, 9: 331–338.

    PubMed  Google Scholar 

  • De Ruvo, N., Cucchetti, A., Lauro, A., Masetti, M., Cautero, N., Di Benedetto, F., Dazzi, A., Del Gaudio, M., Ravaioli, M., Zanello, M., La Barba, G., di Francesco, F., Risaliti, A., Ramacciato, G., Pinna, A.D. (2005). Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation Proceedings, 37: 2607–2608.

    PubMed  Google Scholar 

  • Degos, F., Christidis, C., Ganne-Carrie, N., Farmachidi, J.P., Degott, C., Guettier, C., Trinchet, J.C., Beaugrand, M., Chevret, S. (2000). Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut, 47: 131–136.

    PubMed  CAS  Google Scholar 

  • Di Bisceglie, A.M., Hoofnagle, J.H. (2002). Optimal therapy of hepatitis C. Hepatology, 36 (5 Suppl. 1): S121–127.

    PubMed  Google Scholar 

  • Dousset, B., Conti, F., Houssin, D., Calmus, Y. (1994). Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. New England Journal of Medicine, 330: 1160–1161.

    PubMed  CAS  Google Scholar 

  • Dumortier, J., Scoazec, J.Y., Chevallier, P., Boillot, O. (2004). Treatment of recurrent hepatitis C after liver transplantation: a pilot study of PEGinterferon alpha-2b and ribavirin combination. Journal of Hepatology, 40: 669–674.

    PubMed  CAS  Google Scholar 

  • Durelli, L., Ferrero, B., Oggero, A., Verdun, E., Ghezzi, A., Montanari, E., Zaffaroni, M. (2001). Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. Journal of Clinical Endocrinology & Metabolism, 86: 3525–3532.

    CAS  Google Scholar 

  • Eason, J.D., Nair, S., Cohen, A.J., Blazek, J.L., Loss, G.E., Jr. (2003). Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation, 75: 1396–1399.

    PubMed  CAS  Google Scholar 

  • El-Serag, H.B. (2001). Epidemiology of hepatocellular carcinoma. Clinical Liver Disease, 5: 87–107, vi.

    CAS  Google Scholar 

  • Everson, G.T. (2005). Treatment of hepatitis C in the patient with decompensated cirrhosis. Clinical Gastroenterology and Hepatology, 3 (10 Suppl. 2): S106–112.

    PubMed  CAS  Google Scholar 

  • Everson, G.T., Heathcote, J., Pappas, S.C. (2004a). Histologic benefit of Peg-Interferon alpha 2a (40 KD) (PEGASYS) monotherapy in patients with advanced fibrosis or cirrhosis due to chronic hepatitis C. Hepatology, 40: 316A.

    Google Scholar 

  • Everson, G.T., Hoefs, J.C., Malet, P. (2004b). Impaired virologic response in patients with advanced liver disease due to chronic hepatitis C is independently linked to severity of disease: results from the HALT C trial. Hepatology, 40: 180A.

    Google Scholar 

  • Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J.T., Thomas, H., Njapoum, C., Casarin, C., Bonetti, P., Fuschi, P., Basho, J., Tocco, A., Bhalla, A., Galassini, R., Noventa, F., Schalm, S.W., Realdi, G. (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 112: 463–472.

    PubMed  CAS  Google Scholar 

  • Fattovich, G., Giustina, G., Favarato, S., Ruol, A. (1996). A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. Journal of Hepatology, 24: 38–47.

    PubMed  CAS  Google Scholar 

  • Fattovich, G., Pantalena, M., Zagni, I., Realdi, G., Schalm, S.W., Christensen, E. (2002). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology, 97: 2886–2895.

    PubMed  Google Scholar 

  • Fattovich, G., Stroffolini, T., Zagni, I., Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127 (5 Suppl. 1): S35–50.

    PubMed  Google Scholar 

  • Feray, C., Samuel, D., Gigou, M., Paradis, V., David, M.F., Lemonnier, C., Reynes, M., Bismuth, H. (1995). An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology, 22 (4 Pt. 1): 1084–1089.

    PubMed  CAS  Google Scholar 

  • Forman, L.M., Lewis, J.D., Berlin, J.A., Feldman, H.I., Lucey, M.R. (2002). The association between hepatitis C infection and survival after orthotropic liver transplantation. Gastroenterology, 122: 889–896.

    PubMed  Google Scholar 

  • Forns, X., Ampurdanes, S., Sanchez-Tapias, J.M., Guilera, M., Sans, M., Sanchez-Fueyo, A., Quinto, L., Joya, P., Bruguera, M., Rodes, J. (2001). Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. Journal of Hepatology, 35: 265–271.

    PubMed  CAS  Google Scholar 

  • Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). PEGinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347: 975–982.

    PubMed  CAS  Google Scholar 

  • Gane, E.J., Lo, S.K., Riordan, S.M., Portmann, B.C., Lau, J.Y., Naoumov, N.V., Williams, R. (1998). A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation. Hepatology, 27: 1403–1407.

    PubMed  CAS  Google Scholar 

  • Gane, E.J., Naoumov, N.V., Qian, K.P., Mondelli, M.U., Maertens, G., Portmann, B.C., Lau, J.Y., Williams, R. (1996). A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology, 110: 167–177.

    PubMed  CAS  Google Scholar 

  • Garcia-Retortillo, M., Forns, X., Feliu, A., Moitinho, E., Costa, J., Navasa, M., Rimola, A., Rodes, J. (2002). Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology, 35: 680–687.

    PubMed  Google Scholar 

  • Ghobrial, R.M., Farmer, D.G., Baquerizo, A., Colquhoun, S., Rosen, H.R., Yersiz, H., Markmann, J.F., Drazan, K.E., Holt, C., Imagawa, D., Goldstein, L.I., Martin, P., Busuttil, R.W. (1999). Orthotropic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Annals of Surgery, 229: 824–831; discussion 831–823.

    PubMed  CAS  Google Scholar 

  • Giostra, E., Kullak-Ublick, G.A., Keller, W., Fried, R., Vanlemmens, C., Kraehenbuhl,S., Locher, S., Egger, H.P., Clavien, P.A., Hadengue, A., Mentha, G., Morel, P., Negro, F. (2004). Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transplant International, 17: 169–176.

    PubMed  CAS  Google Scholar 

  • Gordon, A., Mitchell, J.L., Morales, B.M., Thomson, K., Pedersen J.S., McLean, C., Angus, P.W., Roberts, S.K. (2005). Sustained virological response is associated with reduction of HVPG in chronic hepatitis C related cirrhosis. Journal of Hepatology, 42: 205A.

    Google Scholar 

  • Gordon, S.C., Bayati, N., Silverman, A.L. (1998). Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology, 28: 562–567.

    PubMed  CAS  Google Scholar 

  • Gramenzi, A., Andreone, P., Fiorino, S., Camma, C., Giunta, M., Magalotti, D., Cursaro, C., Calabrese, C., Arienti, V., Rossi, C., Di Febo, G., Zoli, M., Craxi, A., Gasbarrini, G., Bernardi, M. (2001). Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut, 48: 843–848.

    PubMed  CAS  Google Scholar 

  • Guerrero, R.B., Batts, K.P., Burgart, L.J., Barrett, S.L., Germer, J.J., Poterucha, J.J., Wiesner, R.H., Charlton, M.R., Persing, D.H. (2000). Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Modern Pathology, 13: 229–237.

    PubMed  CAS  Google Scholar 

  • Hadziyannis, S.J., Sette, H., Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M. (2004). PEGinterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.

    PubMed  CAS  Google Scholar 

  • Heathcote, J., Main, J. (2005). Treatment of hepatitis C. Journal of Viral Hepatitis, 12: 223–235.

    PubMed  CAS  Google Scholar 

  • Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., De Pamphilis, J. (2000). PEGinterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. New England Juornal of Medicine, 343: 1673–1680.

    CAS  Google Scholar 

  • Jain, A., Demetris, A.J., Manez, R., Tsamanadas, A.C., Van Thiel, D., Rakela, J., Starzl, T.E., Fung, J.J. (1998). Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transplantation and Surgery, 4: 197–203.

    PubMed  CAS  Google Scholar 

  • Janssen, H.L., Brouwer, J.T., Nevens, F., Sanchez-Tapias, J.M., Craxi, A., Hadziyannis, S. (1993). Fatal hepatic decompensation associated with interferon alpha. European concerted action on viral hepatitis (Eurohep). British Medical Journal, 306: 107–108.

    PubMed  CAS  Google Scholar 

  • Jen, J.F., Glue, P., Gupta, S., Zambas, D., Hajian, G. (2000). Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Therapeutic Drug Monitoring, 22: 555–565.

    PubMed  CAS  Google Scholar 

  • Kerkar, N., Hadzic, N., Davies, E.T., Portmann, B., Donaldson, P.T., Rela, M., Heaton, N.D., Vergani, D., Mieli-Vergani, G. (1998). De-novo autoimmune hepatitis after liver transplantation. Lancet, 351: 409–413.

    PubMed  CAS  Google Scholar 

  • Kim, W.R. (2002). The burden of hepatitis C in the United States. Hepatology, 36 (5 Suppl. 1): S30–34.

    PubMed  Google Scholar 

  • Kowdley, K.V. (2005). Hematologic side effects of interferon and ribavirin therapy. Jouranl of Clinical Gastroenterology, 39 (1 Suppl.): S3–8.

    CAS  Google Scholar 

  • Kugelmas, M., Osgood, M.J., Trotter, J.F., Bak, T., Wachs, M., Forman, L., Kam, I., Everson, G.T. (2003). Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transplantation, 9: 1159–1165.

    PubMed  Google Scholar 

  • Lake, J.R., Shorr, J.S., Steffen, B.J., Chu, A.H., Gordon, R.D., Wiesner, R.H. (2005). Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. American Journal of Transplantation, 5: 549–557.

    PubMed  Google Scholar 

  • Lee, S.S., Bain, V.G., Peltekian, K., Krajden, M., Yoshida, E.M., Deschenes, M., Heathcote, J., Bailey, R.J., Simonyi, S., Sherman, M. (2006). Treating chronic hepatitis C with PEGylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Alimentary Pharmacology & Therapeutics, 23: 397–408.

    CAS  Google Scholar 

  • Lee, W.M., Dienstag, J.L., Lindsay, K.L., Lok, A.S., Bonkovsky, H.L., Shiffman, M.L., Everson, G.T., Di Bisceglie, A.M., Morgan, T.R., Ghany, M.G., Morishima, C., Wright, E.C., Everhart, J.E. (2004). Evolution of the HALT-C trial: PEGylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials, 25: 472–492.

    PubMed  CAS  Google Scholar 

  • Licata, A., Di Bona, D., Schepis, F., Shahied, L., Craxi, A., Camma, C. (2003). When and how to treat acute hepatitis C? Journal of Hepatology, 39: 1056–1062.

    PubMed  CAS  Google Scholar 

  • Llovet, J.M., Burroughs, A., Bruix, J. (2003). Hepatocellular carcinoma. Lancet, 362: 1907–1917.

    PubMed  Google Scholar 

  • Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001). PEGinterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.

    PubMed  CAS  Google Scholar 

  • Manns, M.P., Wedemeyer, H., Cornberg, M. (2006). Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 55: 1350–1359.

    PubMed  CAS  Google Scholar 

  • Marcos, A., Eghtesad, B., Fung, J.J., Fontes, P., Patel, K., Devera, M., Marsh, W., Gayowski, T., Demetris, A.J., Gray, E.A., Flynn, B., Zeevi, A., Murase, N., Starzl, T.E. (2004). Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation, 78: 966–971.

    PubMed  CAS  Google Scholar 

  • Marrache, F., Consigny, Y., Ripault, M.P., Cazals-Hatem, D., Martinot, M., Boyer, N., Degott, C., Valla, D., Marcellin, P. (2005). Safety and efficacy of PEGinterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. Journal of Viral Hepatitis, 12: 421–428.

    PubMed  CAS  Google Scholar 

  • Mazzella, G., Accogli, E., Sottili, S., Festi, D., Orsini, M., Salzetta, A., Novelli, V., Cipolla, A., Fabbri, C., Pezzoli, A., Roda, E. (1996). Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. Juornal of Hepatology, 24: 141–147.

    CAS  Google Scholar 

  • Mazziotti, G., Sorvillo, F., Morisco, F., Carbone, A., Rotondi, M., Stornaiuolo, G., Precone, D.F., Cioffi, M., Gaeta, G.B., Caporaso, N., Carella, C. (2002). Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer, 95: 2539–2545.

    PubMed  CAS  Google Scholar 

  • McCaughan, G.W., Zekry, A. (2002). Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transplantation, 8 (10 Suppl. 1): S7–S13.

    PubMed  Google Scholar 

  • McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. (1998). Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339: 1485–1492.

    PubMed  CAS  Google Scholar 

  • Mukherjee, S. (2005). PEGylated interferon alpha-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplantation Proceedings, 37: 4403–4405.

    PubMed  CAS  Google Scholar 

  • Nakagawa, M., Sakamoto, N., Enomoto, N., Tanabe, Y., Kanazawa, N., Koyama, T., Kurosaki, M., Maekawa, S., Yamashiro, T., Chen, C.H., Itsui, Y., Kakinuma, S., Watanabe, M. (2004). Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochemical and Biophysical Research Communications, 313: 42–47.

    PubMed  CAS  Google Scholar 

  • Nakagawa, M., Sakamoto, N., Tanabe, Y., Koyama, T., Itsui, Y., Takeda, Y., Chen, C.H., Kakinuma, S., Oooka, S., Maekawa, S., Enomoto, N., Watanabe, M. (2005). Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology, 129: 1031–1041.

    PubMed  CAS  Google Scholar 

  • Neff, G.W., Montalbano, M., O’Brien, C.B., Nishida, S., Safdar, K., Bejarano, P.A., Khaled, A.S., Ruiz, P., Slapak-Green, G., Lee, M., Nery, J., De Medina, M., Tzakis, A., Schiff, E.R. (2004). Treatment of established recurrent hepatitis C in liver-transplant recipients with PEGylated interferon-alpha-2b and ribavirin therapy. Transplantation, 78: 1303–1307.

    PubMed  CAS  Google Scholar 

  • Neumann, U.P., Berg, T., Bahra, M., Seehofer, D., Langrehr, J.M., Neuhaus, R., Radke, C., Neuhaus, P. (2004). Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. Journal of Hepatology, 41: 830–836.

    PubMed  CAS  Google Scholar 

  • Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C.M., Mohr, L., Haussinger, D. (1996). Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. New England Journal of Medicine, 334: 1422–1427.

    PubMed  CAS  Google Scholar 

  • Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., Haussinger, D. (1998). Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 28: 1687–1695.

    PubMed  CAS  Google Scholar 

  • NIH Consensus Statement on Management of Hepatitis C: 2002. (2002). NIH Consensus and State of the Science Statements, 19: 1–46.

    Google Scholar 

  • Papatheodoridis, G.V., Manesis, E., Hadziyannis, S.J. (2001). The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. Journal of Hepatology, 34: 306–313.

    PubMed  CAS  Google Scholar 

  • Parkin, D.M., Bray, F., Ferlay, J., Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. International Journal of Cancer, 94: 153–156.

    CAS  Google Scholar 

  • Pelletier, S.J., Raymond, D.P., Crabtree, T.D., Berg, C.L., Iezzoni, J.C., Hahn, Y.S., Sawyer, R.G., Pruett, T.L. (2000). Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology, 32: 418–426.

    PubMed  CAS  Google Scholar 

  • Pelletier, S.J., Raymond, D.P., Crabtree, T.D., Iezzoni, J.C., Sawyer, R.G., Hahn, Y.S., Pruett, T.L. (2000). Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation. Hepatology, 32: 375–381.

    PubMed  CAS  Google Scholar 

  • Planas, R., Balleste, B., Alvarez, M.A., Rivera, M., Montoliu, S., Galeras, J.A., Santos, J., Coll, S., Morillas, R.M., Sola, R. (2004). Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. Journal of Hepatology, 40: 823–830.

    PubMed  Google Scholar 

  • Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M.H., Albrecht, J. (2002). Impact of PEGylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 122: 1303–1313.

    PubMed  CAS  Google Scholar 

  • Poynard, T., Schiff, E., Terg, R., Goncales, F., Diago, M., Reichen, J., Moreno, R, Bedossa, P., Burroughs, M., Albrecht, J. (2005). Sustained virologic response (SVR) in EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD). Journal of Hepatology, 42: 40A.

    Google Scholar 

  • Prieto, M., Berenguer, M., Rayon, J.M., Cordoba, J., Arguello, L., Carrasco, D., Garcia-Herola, A., Olaso, V., De Juan, M., Gobernado, M., Mir, J., Berenguer, J. (1999). High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology, 29: 250–256.

    PubMed  CAS  Google Scholar 

  • Rifai, K., Sebagh, M., Karam, V., Saliba, F., Azoulay, D., Adam, R., Castaing, D., Bismuth, H., Reynes, M., Samuel, D., Feray, C. (2004). Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. Journal of Hepatology, 41: 446–453.

    PubMed  Google Scholar 

  • Rodriguez-Luna, H., Khatib, A., Sharma, P., De Petris, G., Williams, J.W., Ortiz, J., Hansen, K., Mulligan, D., Moss, A., Douglas, D.D., Balan, V., Rakela, J., Vargas, H.E. (2004). Treatment of recurrent hepatitis C infection after liver transplantation with combination of PEGylated interferon alpha2b and ribavirin: an open-label series. Transplantation, 77: 190–194.

    PubMed  CAS  Google Scholar 

  • Rosen, H.R., Shackleton, C.R., Higa, L., Gralnek, I.M., Farmer, D.A., McDiarmid, S.V., Holt, C., Lewin, K.J., Busuttil, R.W., Martin, P. (1997). Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. American Journal of Gastroenterology, 92: 1453–1457.

    PubMed  CAS  Google Scholar 

  • Saito, Y., Saito, H., Tada, S., Nakamoto, N., Horikawa, H., Kurita, S., Kitamura, K., Ebinuma, H., Ishii, H., Hibi, T. (2005). Effect of long-term interferon therapy for refractory chronic hepatitis C: preventive effect on hepatocarcinogenesis. Hepatogastroenterology, 52: 1491–1496.

    PubMed  CAS  Google Scholar 

  • Salcedo, M., Vaquero, J., Banares, R., Rodriguez-Mahou, M., Alvarez, E., Vicario, J.L., Hernandez-Albujar, A., Tiscar, J.L., Rincon, D., Alonso, S., De Diego, A., Clemente, G. (2002). Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology, 35: 349–356.

    PubMed  CAS  Google Scholar 

  • Samuel, C.E. (2001). Antiviral actions of interferons. Clinical Microbiology Reviews, 14: 778–809, table of contents.

    PubMed  CAS  Google Scholar 

  • Samuel, D., Bizollon, T., Feray, C., Roche, B., Ahmed, S.N., Lemonnier, C., Cohard, M., Reynes, M., Chevallier, M., Ducerf, C., Baulieux, J., Geffner, M., Albrecht, J.K., Bismuth, H., Trepo, C. (2003). Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology, 124: 642–650.

    PubMed  CAS  Google Scholar 

  • Samuel, D., Forns, X., Berenguer, M., Trautwein, C., Burroughs, A., Rizzetto, M., Trepo, C. (2006). Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). Journal of Hepatology, 45: 127–143.

    PubMed  Google Scholar 

  • Sanchez-Fueyo, A., Restrepo, J.C., Quinto, L., Bruguera, M., Grande, L., Sanchez-Tapias, J.M., Rodes, J., Rimola, A. (2002). Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation, 73: 56–63.

    PubMed  Google Scholar 

  • Serfaty, L., Aumaitre, H., Chazouilleres, O., Bonnand, A.M., Rosmorduc, O., Poupon, R.E., Poupon, R. (1998). Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 27: 1435–1440.

    PubMed  CAS  Google Scholar 

  • Sheiner, P.A., Schwartz, M.E., Mor, E., Schluger, L.K., Theise, N., Kishikawa, K., Kolesnikov, V., Bodenheimer, H., Emre, S., Miller, C.M. (1995). Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotropic liver transplantation. Hepatology, 21: 30–34.

    PubMed  CAS  Google Scholar 

  • Shergill, A.K., Khalili, M., Straley, S., Bollinger, K., Roberts, J.P., Ascher, N.A., Terrault, N.A. (2005). Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. American Journal of Transplantation, 5: 118–124.

    PubMed  Google Scholar 

  • Shiffman, M.L., Hofmann, C.M., Thompson, E.B., Ferreira-Gonzalez, A., Contos, M.J., Koshy, A., Luketic, V.A., Sanyal, A.J., Mills, A.S., Garrett, C.T. (1997). Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology, 26: 780–785.

    PubMed  CAS  Google Scholar 

  • Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., Arakawa, Y., Hashimoto, E., Hirota, K., Yoshida, H., Ohashi, Y., Omata, M. (2005). Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Annals of Internal Medicine, 142: 105–114.

    PubMed  CAS  Google Scholar 

  • Singh, N., Gayowski, T., Wannstedt, C.F., Shakil, A.O., Wagener, M.M., Fung, J.J., Marino, I.R. (1998). Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation, 65: 82–86.

    PubMed  CAS  Google Scholar 

  • Stravitz, R.T., Shiffman, M.L., Sanyal, A.J., Luketic, V.A., Sterling, R.K., Heuman, D.M., Ashworth, A., Mills, A.S., Contos, M., Cotterell, A.H., Maluf, D., Posner, M.P., Fisher, R.A. (2004). Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transplantation, 10: 850–858.

    PubMed  Google Scholar 

  • Sugawara, Y., Makuuchi, M., Matsui, Y., Kishi, Y., Akamatsu, N., Kaneko, J., Kokudo, N. (2004). Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation, 78: 1308–1311.

    PubMed  CAS  Google Scholar 

  • Terrault, N.A. (2005). Treatment of recurrent hepatitis C in liver transplant recipients. Clinical Gastroenterology and Hepatology, 3 (10 Suppl. 2): S125–131.

    PubMed  CAS  Google Scholar 

  • Thomas, R.M., Brems, J.J., Guzman-Hartman, G., Yong, S., Cavaliere, P., Van Thiel, D.H. (2003). Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transplantation, 9: 905–915.

    PubMed  Google Scholar 

  • Tong, M.J., el-Farra, N.S., Reikes, A.R., Co, R.L. (1995). Clinical outcomes after transfusion-associated hepatitis C. New England Journal of Medicine, 332: 1463–1466.

    PubMed  CAS  Google Scholar 

  • Toniutto, P., Fabris, C., Fumo, E., Apollonio, L., Caldato, M., Avellini, C., Minisini, R., Pirisi, M. (2005). PEGylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. Journal of Gastroenterology and Hepatology, 20: 577–582.

    PubMed  CAS  Google Scholar 

  • Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993). Risk factors for hepatocellular carcinoma among patients with chronic liver disease. New England Journal of Medicine, 328: 1797–1801.

    PubMed  CAS  Google Scholar 

  • Valla, D.C., Chevallier, M., Marcellin, P., Payen, J.L., Trepo, C., Fonck, M., Bourliere, M., Boucher, E., Miguet, J.P., Parlier, D., Lemonnier, C., Opolon, P. (1999). Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology, 29: 1870–1875.

    PubMed  CAS  Google Scholar 

  • Velazquez, R.F., Rodriguez, M., Navascues, C.A., Linares, A., Perez, R., Sotorrios, N.G., Martinez, I., Rodrigo, L. (2003). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 37: 520–527.

    PubMed  Google Scholar 

  • Wang, C.S., Ko, H.H., Yoshida, E.M., Marra, C.A., Richardson, K. (2006). Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. American Journal of Transplantation, 6: 1586–1599.

    PubMed  CAS  Google Scholar 

  • Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., Shimotohno, K. (2003). Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 38: 1282–1288.

    PubMed  CAS  Google Scholar 

  • WHO (1999). World Health Organization. Weekly Epidemiological Record, pp. 421–428.

    Google Scholar 

  • Wiesner, R.H., Sorrell, M., Villamil, F. (2003). Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplantation, 9: S1–9.

    PubMed  Google Scholar 

  • Wilson, L.E., Widman, D., Dikman, S.H., Gorevic, P.D. (2002). Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Seminars in Arthritis and Rheumatism, 32: 163–173.

    PubMed  Google Scholar 

  • Wright, T.L., Combs, C., Kim, M., Ferrell, L., Bacchetti, P., Ascher, N., Roberts, J., Wilber, J., Sheridan, P., Urdea, M. (1994). Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology, 20 (4 Pt. 1): 773–779.

    PubMed  CAS  Google Scholar 

  • Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Lefkowitch, J.H., Ludwig, J., Okuda, K. (1996). The long-term pathological evolution of chronic hepatitis C. Hepatology, 23: 1334–1340.

    PubMed  CAS  Google Scholar 

  • Yedibela, S., Schuppan, D., Muller, V., Schellerer, V., Tannapfel, A., Hohenberger, W., Meyer, T. (2005). Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver International, 25: 717–722.

    PubMed  CAS  Google Scholar 

  • Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S., Yamada, G., Omata, M. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Annals of Internal Medicine, 131:174–181.

    PubMed  CAS  Google Scholar 

  • Yoshida, H., Tateishi, R., Arakawa, Y., Sata, M., Fujiyama, S., Nishiguchi, S., Ishibashi, H., Yamada, G., Yokosuka, O., Shiratori, Y., Omata, M. (2004). Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut, 53: 425–430.

    PubMed  CAS  Google Scholar 

  • Zeuzem, S., Schmidt, J.M., Lee, J.H., Ruster, B., Roth, W.K. (1996). Effect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology, 23: 366–371.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento diMedicina Interna e Gastroenterologia, Policlinico S.Orsola-Malpighi, Via Massarenti 9, 40138 Bologna, Italy

    Davide Festi MD

Authors
  1. Davide Festi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Lodato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Mazzella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Colecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Bari and National Institute for Digestive Disease, Castellana Grotte, Bari, Italy

    Emilio Jirillo

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Festi, D., Lodato, F., Mazzella, G., Colecchia, A. (2008). Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. In: Jirillo, E. (eds) Hepatitis C Virus Disease. Springer, New York, NY. https://doi.org/10.1007/978-0-387-71376-2_11

Download citation

Publish with us

Policies and ethics

Search

Navigation